Day: June 13, 2022

rad-at-the-movies Illustration of RAD SCOT, ROSA 3.0, and ROAMEO security robots in a simulated autonomous response mode on a film countdown reel. RAD has now participated in 3 film productions and 1 television series with more expected.Detroit, Michigan, June 13, 2022 (GLOBE NEWSWIRE) — Artificial Intelligence Technology Solutions, Inc., (OTCPK:AITX), today announced that its wholly owned subsidiary Robotic Assistance Devices, Inc. (RAD) is presently in the shooting schedule of its third film production and one television series. RAD devices have been sought after by film directors, production designers and television show runners due to their unique, hi-tech appearance and their inherent ability to interact with the story’s characters. The Company noted that it is not paying for the placement of its devices in these productions...

The Annual Stockholder Meeting on Friday, June 17, 2022 at 10 am ET DALLAS, June 13, 2022 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that its annual stockholder meeting will be held on Friday, June 17, 2022 at 10 am ET via webcast. The webcast for this meeting will be available in the “Events & Presentations” section of the Taysha corporate website. A copy of Taysha’s 2021 annual report is available here and in the “Financial Information” section of the Taysha Corporate Website. About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is on a...

Study Results Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting NORTH BILLERICA, Mass., June 13, 2022 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH) is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus presented preliminary results of the PD-L1 Expression in Cancer (PECan) study at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting. The results suggest that NM-01, a proprietary technetium 99m SPECT/CT imaging agent currently under development to assess PD-L1 expression in cancer cells, has the potential to identify patients who will respond to checkpoint inhibitor therapies and monitor early response in non-small...

Featuring mouth-watering fruity flavours steeping faster than ever, the Cold Brew Collection will keep you feeling refreshed all summer long.PR Cold Brew DAVIDsTEA launches Cold Brew CollectionMONTRÉAL, June 13, 2022 (GLOBE NEWSWIRE) — DAVIDsTEA Inc. (Nasdaq:DTEA), a leading tea merchant in North America, is pleased to announce the launch of their most innovative collection of cold brew teas for summer 2022. Brand new blends and accessories are available at all 18 DAVIDsTEA flagship stores across Canada, and online at davidstea.com. DAVIDsTEA is diving into summer with the most innovative take on cold brew iced tea. While most loose leaf cold brew teas on the market take over 8 hours to infuse, DAVIDsTEA’s are some of the quickest available—instead of their previous 1.5-hour steep time, their new Cold Brew Teas steep in only...

SAN JOSE, Calif., June 13, 2022 (GLOBE NEWSWIRE) — Infinera (NASDAQ: INFN) announced today that OTEGLOBE, a leading wholesale carrier in the southeastern Europe region, selected Infinera’s ICE6 800G coherent solution for its pan-European network. By deploying Infinera’s ICE6, OTEGLOBE will double capacity in selected parts of its diverse terrestrial backbone network and offer new 400 GbE services to its customers. OTEGLOBE’s pan-European network, with more than 21,000 km of fiber, spans Greece, the Balkans, Italy, and Eastern and Western Europe, and connects to major European gateways over multiple diverse fiber routes to offer unparalleled and seamless connectivity throughout the region. With Infinera’s ICE6 solution on the GX G42 Compact Modular Platform deployed on this pan-European backbone, OTEGLOBE benefits from new high-performance,...

Use Includes Pelvic Fragility FracturesiFuse-TORQ® Implant System iFuse-TORQ® Implant SystemSANTA CLARA, Calif., June 13, 2022 (GLOBE NEWSWIRE) — SI-BONE, Inc. (SIBN), (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced an FDA clearance for iFuse-TORQ® for pelvic fracture fixation, including acute, non-acute and non-traumatic fractures.* Fractures covered in this clearance include pelvic fragility fractures (fractures related to low-energy traumatic events) and pelvic insufficiency fractures. Together, these constitute an approximately $300 million market opportunity. Sacral fragility and insufficiency fractures are common and often devastating for patients and healthcare systems, where:120,000 sacral fragility or insufficiency...

– Treatment with encaleret resulted in rapid and sustained restoration of normal mineral homeostasis, with mean values of blood calcium, urinary calcium, and blood PTH within the normal range by day 5 of therapy and sustained at 24 weeks, and was well-tolerated without any reported serious adverse events – At week 24 of encaleret treatment, 92% (12/13) of participants had achieved normal trough blood calcium levels in the absence of extra-dietary calcium supplements and active vitamin D, and 77% (10/13) of participants had normal urinary calcium excretion – The Company completed its end of Phase 2 interaction with the US FDA; the Phase 3 pivotal study is anticipated to begin in 2022 and will evaluate a primary composite endpoint of blood and urinary calcium within target ranges in participants treated with encaleret...

LEXINGTON, Mass., June 13, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced results from a preclinical study of RKER-012 on cardiac and pulmonary pathology in an established rodent model of pulmonary arterial hypertension (“PAH”), which were presented at the Pulmonary Hypertension Association International Conference and Scientific Sessions held on June 10 through 12, 2022.   RKER-012 reduced cardiac and pulmonary pathology in a rodent PAH model.RKER-012, a Novel Activin Receptor Type IIB (“ActRIIB”) Ligand Trap, Reduced Cardiac and Pulmonary Pathology...

Vancouver, BC, June 13, 2022 (GLOBE NEWSWIRE) — Skyharbour Resources Ltd.’s (TSX-V: SYH) (OTCQB: SYHBF) (Frankfurt: SC1P) (the “Company”) is pleased to announce that it has commenced an airborne gravity geophysical survey (the “Survey”) at its 44,470 hectare South Falcon Point Uranium Property (the “Property”) located just outside the Athabasca Basin 48 kilometres east of the Key Lake Mill. The 100% owned South Falcon Point Property is host to a near-surface NI 43-101 inferred resource totalling 7.0 million pounds of U3O8 at 0.03% and 5.3 million pounds of ThO2 at 0.023%. South Falcon Point Project Location Map:https://www.skyharbourltd.com/_resources/maps/Sky_FalconSouth20211209.jpg The Survey consists of a Falcon® Plus airborne gravity gradiometer and magnetics survey by Xcalibur Multiphysics of Mississauga, ON. Falcon® is the...